Compare HLIO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | AGIO |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1996 | 2013 |
| Metric | HLIO | AGIO |
|---|---|---|
| Price | $83.04 | $32.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $66.17 | $38.88 |
| AVG Volume (30 Days) | 255.3K | ★ 1.1M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $200,727,000.00 | $43,011,000.00 |
| Revenue This Year | $3.67 | $76.75 |
| Revenue Next Year | $5.00 | $170.73 |
| P/E Ratio | $139.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.05 | $22.24 |
| 52 Week High | $95.05 | $46.00 |
| Indicator | HLIO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 38.40 |
| Support Level | $78.81 | $26.71 |
| Resistance Level | $83.99 | $36.07 |
| Average True Range (ATR) | 2.60 | 2.01 |
| MACD | 0.46 | -0.85 |
| Stochastic Oscillator | 75.89 | 24.67 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.